Stock HQY HEALTHEQUITY, INC.
Add to a list
To use this feature you must be a member
Log inSign up
PDF Report : HealthEquity, Inc.

Consensus HealthEquity, Inc.

Equities

HQY

US42226A1079

Market Closed - Nasdaq
Other stock markets
 04:00:00 2023-12-06 pm EST 		Intraday chart for HealthEquity, Inc. 5-day change 1st Jan Change
69.33 USD +0.45% +5.09% +12.48%
Dec. 06 Wells Fargo Adjusts HealthEquity's Price Target to $93 From $89, Maintains Overweight Rating MT
Dec. 05 HealthEquity's Fiscal Q3 Non-GAAP Earnings, Revenue Rise MT

Evolution of the average Target Price on HealthEquity, Inc.

Price target over the last 5 years

History : Analyst Recommendations

a8a998fe162410cd.jyf9tEC3qFv9XyqbTM0n4NnJHEMgKAMpeWjKEhj3Lns.vECr4XDt7j-fFlKqD559s5W4fzpqWnVhFFmZdVPOTR_rU7rFdPbMLrQnaw~6047dc7ef3e0b987121b4766c8992a8b

Analyst Recommendations on HealthEquity, Inc.

Wells Fargo Adjusts HealthEquity's Price Target to $93 From $89, Maintains Overweight Rating MT
Deutsche Bank Raises HealthEquity's Price Target to $85 From $72, Maintains Buy Rating MT
Baird Upgrades HealthEquity to Outperform From Neutral, Raises Price Target to $87 From $79 MT
Deutsche Bank Adjusts HealthEquity Price Target to $72 From $71, Maintains Buy Rating MT
RBC Lifts PT on HealthEquity to $77 From $75 After Fiscal Q2 Beat, Fiscal 2024 Guidance, Keeps Outperform Rating MT
Baird Adjusts Price Target on HealthEquity to $79 From $77, Maintains Neutral Rating MT
Barrington Raises PT on HealthEquity to $85 From $80 After Fiscal Q2 Results Surpass Expectations, Maintains Outperform Rating MT
RBC Lifts Price Target on HealthEquity to $77 From $75 After Fiscal Q2 Beat, Fiscal 2024 Guidance Boost, Keeps Outperform Rating MT
JPMorgan Cuts HealthEquity's Price Target to $81 From $84, Maintains Overweight Rating MT
Deutsche Bank Adjusts HealthEquity Price Target to $71 From $69, Maintains Buy Rating MT
Deutsche Bank Adjusts HealthEquity Price Target to $69 From $72, Maintains Buy Rating MT
Wells Fargo Adjusts Price Target on HealthEquity to $89 From $101, Maintains Overweight Rating MT
Deutsche Bank Adjusts HealthEquity's Price Target to $72 From $68, Maintains Buy Rating MT
Raymond James Adjusts HealthEquity Price Target to $85 From $75, Maintains Outperform Rating MT
Wells Fargo Adjusts Price Target on HealthEquity to $101 From $104, Maintains Overweight Rating MT
Guggenheim Adjusts HealthEquity's Price Target to $94 From $89, Keeps Buy Rating MT
HealthEquity Receives Price Target Boost to $75 From $70 From RBC Amid Expectations for Higher Custodial Revenue; Outperform Rating Kept MT
Wells Fargo Raises HealthEquity's Price Target to $104 From $100, Keeps Overweight Rating MT
Goldman Sachs Upgrades HealthEquity to Neutral From Sell, Adjusts Price Target to $77 From $64 MT
Barrington Research Raises HealthEquity's Price Target to $80 From $75, Maintains Outperform Rating MT
KeyBanc Starts HealthEquity at Overweight With $85 Price Target MT
Wells Fargo Securities Raises HealthEquity's Price Target to $100 From $95, Maintains Overweight Rating MT
Raymond James Adjusts HealthEquity's Price Target to $75 from $70, Maintains Outperform Rating MT
Deutsche Bank Adjusts HealthEquity Price Target to $68 From $67, Maintains Buy Rating MT
Baird Adjusts HealthEquity's Price Target to $67 From $47, Reiterates Neutral Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
69.33USD
Average target price
86.83USD
Spread / Average Target
+25.25%
High Price Target
110USD
Spread / Highest target
+58.66%
Low Price Target
73USD
Spread / Lowest Target
+5.29%

Consensus detail

Consensus revision (last 18 months)

Analysts covering HealthEquity, Inc.

Wells Fargo Securities
Deutsche Bank Securities
Baird
RBC Capital Markets
Barrington Research
JPMorgan Chase
Raymond James
Guggenheim
Goldman Sachs
KeyBanc Capital Markets
SVB Securities LLC
BTIG
Jefferies & Co.
BofA Securities
Stephens Inc.
SVB Leerink
Cantor Fitzgerald

Ratings for HealthEquity, Inc.

Trading Rating :
Investor Rating :
ESG Refinitiv :
B+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock
  2. Equities
  3. Stock HealthEquity, Inc. - Nasdaq
  4. Consensus HealthEquity, Inc.
As early as today, start finding the best investment opportunities!
Optimize my profits
fermer